Atterocor is a drug development company focused on the accelerated development of a novel treatment for adrenal cancer,
a rare endocrine cancer.

Learn More

December 11, 2014
Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers Read More >>

November 12, 2014
Atterocor Appoints Pharis Mohideen, M.D., as Chief Medical Officer Read More >>